Cargando…
Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363237/ https://www.ncbi.nlm.nih.gov/pubmed/27278095 http://dx.doi.org/10.1111/dme.13160 |
| _version_ | 1782517129883418624 |
|---|---|
| author | Smits, M. M. Tonneijck, L. Muskiet, M. H. A. Diamant, M. Kramer, M. H. H. Cahen, D. L. van Raalte, D. H. |
| author_facet | Smits, M. M. Tonneijck, L. Muskiet, M. H. A. Diamant, M. Kramer, M. H. H. Cahen, D. L. van Raalte, D. H. |
| author_sort | Smits, M. M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5363237 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53632372017-04-06 Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes Smits, M. M. Tonneijck, L. Muskiet, M. H. A. Diamant, M. Kramer, M. H. H. Cahen, D. L. van Raalte, D. H. Diabet Med Letters John Wiley and Sons Inc. 2017-03-15 2017-04 /pmc/articles/PMC5363237/ /pubmed/27278095 http://dx.doi.org/10.1111/dme.13160 Text en © 2016 Diabetes UK This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Letters Smits, M. M. Tonneijck, L. Muskiet, M. H. A. Diamant, M. Kramer, M. H. H. Cahen, D. L. van Raalte, D. H. Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes |
| title | Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes |
| title_full | Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes |
| title_fullStr | Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes |
| title_full_unstemmed | Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes |
| title_short | Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes |
| title_sort | acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in type 2 diabetes |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363237/ https://www.ncbi.nlm.nih.gov/pubmed/27278095 http://dx.doi.org/10.1111/dme.13160 |
| work_keys_str_mv | AT smitsmm acuteplasmaamylaseincreaseafterglucagonlikepeptide1receptoragonistexenatideadministrationintype2diabetes AT tonneijckl acuteplasmaamylaseincreaseafterglucagonlikepeptide1receptoragonistexenatideadministrationintype2diabetes AT muskietmha acuteplasmaamylaseincreaseafterglucagonlikepeptide1receptoragonistexenatideadministrationintype2diabetes AT diamantm acuteplasmaamylaseincreaseafterglucagonlikepeptide1receptoragonistexenatideadministrationintype2diabetes AT kramermhh acuteplasmaamylaseincreaseafterglucagonlikepeptide1receptoragonistexenatideadministrationintype2diabetes AT cahendl acuteplasmaamylaseincreaseafterglucagonlikepeptide1receptoragonistexenatideadministrationintype2diabetes AT vanraaltedh acuteplasmaamylaseincreaseafterglucagonlikepeptide1receptoragonistexenatideadministrationintype2diabetes |